Kindred Bio to Host Investor Breakfast on June 13 in New York... -- SAN FRANCISCO, June 11, 2014 /PRNewswire/ --

Kindred Bio to Host Investor Breakfast on June 13 in New York City

SAN FRANCISCO, June 11, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will host an Investor Breakfast on Friday, June 13, 2014 in New York City. Kindred Bio's executive management team will provide an overview of the Company's strategies and Stephen Sundlof, D.V.M, Ph.D., will offer insights into the animal health business from an FDA perspective.

Dr. Sundlof was appointed the Senior Vice President of Regulatory Affairs at Kindred Bio in August 2013. He served as the Director of the Center for Veterinary Medicine at the FDA from 1994 to 2008, where he oversaw all veterinary products regulated by the FDA.

The presentations, followed by a question-and-answer session, will be webcast live beginning at 8am Eastern Time. The webcast will be accessible live and archived on the Investor Relations section of Kindred Bio's website at www.kindredbio.com.

About Kindred Biosciences

Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company's lead product candidates are CereKin™ (diacerein) for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin™ (fexofenadine) for the treatment of atopic dermatitis in dogs, and SentiKin™ (flupirtine) for the treatment of post-operative pain in dogs.